JONATHAN L. DAVIS, M.D.; THOMAS A. SCHULTZ, M.D.; COLEMAN A. MOSLEY, M.D.
Metronidazole, a synthetic nitro-imidazole derivative, is widely used in the treatment of infections due to Entamoeba histolytica, Giardia lamblia, and many obligately anaerobic bacteria (1). Although the drug is usually well tolerated, it has numerous side effects including nausea, metallic taste, urethral burning, dark urine, neutropenia, and peripheral neuropathies (2). It has also been shown to be carcinogenic in both rats and mice (3). Recently, we found a significant drop in both cholesterol and trigylceride levels in a patient during metronidazole therapy for giardiasis. This finding prompted a subsequent evaluation of the cholesterol and trigylceride responses in five other patients
JONATHAN L. DAVIS, THOMAS A. SCHULTZ, COLEMAN A. MOSLEY. Metronidazole Lowers Serum Lipids. Ann Intern Med. 1983;99:43–44. doi: 10.7326/0003-4819-99-1-43
Download citation file:
Published: Ann Intern Med. 1983;99(1):43-44.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use